Biological Markers of Disease Activity in Inflammatory Bowel Diseases

Overview

Journal Prz Gastroenterol

Publisher Termedia

Specialty Gastroenterology

Date 2023 Aug 4

PMID 37538284

Authors

Edyta Szymanska

Sylwia Szymanska

Maciej Dadalski

Jaroslaw Kierkus

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel diseases (IBD) are chronic intestinal conditions of multifactorial aetiology including genetic susceptibility, immunological impairment, dysbiosis, and environmental factors. The diagnosis is based on both clinical and endoscopic features, wherein histopathological evaluation remains a gold diagnostic standard. However, fast, reliable, and non-invasive biological markers have been used for years for diagnosis as well as for disease activity monitoring. Currently, commonly used faecal calprotectin is the only biomarker approved and recommended by the European Crohn's and Colitis Organization (ECCO). Nonetheless, other biological markers discriminating between functional and organic bowel conditions have been widely studied. Therefore, the aim of this manuscript was to review new potential biomarkers of inflammation in IBD. The aim of this study was to review currently available biomarkers of intestinal inflammation and increased gut permeability in IBD.

Citing Articles

Association Between Left Ventricular Diastolic Dysfunction, Systemic Inflammation, and Gastrointestinal Symptoms in HIV-Positive Patients on Antiretroviral Therapy.

Suba M, Hogea B, Abu-Awwad A, Lazureanu V, Rosca O, Gurgus D Diseases. 2024; 12(12.

PMID: 39727643 PMC: 11726855. DOI: 10.3390/diseases12120313.

LRa05 mediates dynamic regulation of intestinal microbiota in mice with low-dose DSS-induced chronic mild inflammation.

Dong Y, Gai Z, Han M, Zhao Y Front Microbiol. 2024; 15:1483104.

PMID: 39444683 PMC: 11496787. DOI: 10.3389/fmicb.2024.1483104.

The Diagnostic Utility of Biochemical Markers and Intestinal Ultrasound Compared with Endoscopy in Patients with Crohn's Disease and Ulcerative Colitis: A Systemic Review and Meta-Analysis.

Huynh D, Rubtsov D, Basu D, Khaing M J Clin Med. 2024; 13(11).

PMID: 38892741 PMC: 11172975. DOI: 10.3390/jcm13113030.

Enhancing Calprotectin's Predictive Power as a Biomarker of Endoscopic Activity in Ulcerative Colitis: A Machine Learning Use Case.

Dranga M, Mihai C, Gavrilescu O, Prelipcean C, Popa I Biomedicines. 2024; 12(3).

PMID: 38540089 PMC: 10968359. DOI: 10.3390/biomedicines12030475.

Intestinal changes in permeability, tight junction and mucin synthesis in a mouse model of Alzheimer's disease.

He J, Liu Y, Li J, Zhao Y, Jiang H, Luo S Int J Mol Med. 2023; 52(6).

PMID: 37830152 PMC: 10599350. DOI: 10.3892/ijmm.2023.5316.

References

Walker T, Land M, Kartashov A, Saslowsky T, Lyerly D, Boone J . Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44(4):414-22. DOI: 10.1097/MPG.0b013e3180308d8e. View

Lewis J . The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140(6):1817-1826.e2. PMC: 3749298. DOI: 10.1053/j.gastro.2010.11.058. View

Zollner A, Schmiderer A, Reider S, Oberhuber G, Pfister A, Texler B . Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study. J Crohns Colitis. 2020; 15(1):43-54. DOI: 10.1093/ecco-jcc/jjaa124. View

Fasano A . Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011; 91(1):151-75. DOI: 10.1152/physrev.00003.2008. View

Vermeire S, Van Assche G, Rutgeerts P . Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006; 55(3):426-31. PMC: 1856093. DOI: 10.1136/gut.2005.069476. View

Piton G, Capellier G . Biomarkers of gut barrier failure in the ICU. Curr Opin Crit Care. 2016; 22(2):152-60. DOI: 10.1097/MCC.0000000000000283. View

Duarte-Silva M, Afonso P, de Souza P, Peghini B, Rodrigues-Junior V, de Barros Cardoso C . Reappraisal of antibodies against Saccharomyces cerevisiae (ASCA) as persistent biomarkers in quiescent Crohn's disease. Autoimmunity. 2019; 52(1):37-47. DOI: 10.1080/08916934.2019.1588889. View

Levay P, Viljoen M . Lactoferrin: a general review. Haematologica. 1995; 80(3):252-67. View

Zhou G, Song Y, Yang W, Guo Y, Fang L, Chen Y . ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?. Dig Dis. 2016; 34(1-2):90-7. DOI: 10.1159/000442934. View

10.

Zhang W, Teng G, Wu T, Tian Y, Wang H . Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(12):2134-2141. DOI: 10.1097/MIB.0000000000001252. View

11.

Wiedow O, Schroder J, Gregory H, Young J, Christophers E . Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990; 265(25):14791-5. View

12.

Papp M, Lakatos P, Palatka K, Foldi I, Udvardy M, Harsfalvi J . Haptoglobin polymorphisms are associated with Crohn's disease, disease behavior, and extraintestinal manifestations in Hungarian patients. Dig Dis Sci. 2007; 52(5):1279-84. DOI: 10.1007/s10620-006-9615-1. View

13.

Behnsen J, Jellbauer S, Wong C, Edwards R, George M, Ouyang W . The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity. 2014; 40(2):262-73. PMC: 3964146. DOI: 10.1016/j.immuni.2014.01.003. View

14.

Li N, Wang X, Zhang Y, Zhai J, Zhang T, Wei K . Comparative proteomics analysis of serum proteins in ulcerative colitis patients. Mol Biol Rep. 2011; 39(5):5659-67. DOI: 10.1007/s11033-011-1373-2. View

15.

Baynes R, Bezwoda W . Lactoferrin and the inflammatory response. Adv Exp Med Biol. 1994; 357:133-41. DOI: 10.1007/978-1-4615-2548-6_13. View

16.

de Bruyn M, Arijs I, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P . Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2015; 9(12):1079-87. DOI: 10.1093/ecco-jcc/jjv148. View

17.

Mitchell P, Rabau M, Haboubi N . Indeterminate colitis. Tech Coloproctol. 2007; 11(2):91-6. DOI: 10.1007/s10151-007-0337-y. View

18.

Garcia-Planella E, Manosa M, Chaparro M, Beltran B, Barreiro-De-Acosta M, Gordillo J . Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. Scand J Gastroenterol. 2017; 53(2):152-157. DOI: 10.1080/00365521.2017.1410219. View

19.

Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L . Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005; 51(3-4):117-26. View

20.

Szymanska E, Bierla J, Dadalski M, Wierzbicka A, Konopka E, Cukrowska B . New noninvasive biomarkers of intestinal inflammation and increased intestinal permeability in pediatric inflammatory bowel diseases and their correlation with fecal calprotectin: a pilot study. Minerva Gastroenterol (Torino). 2022; 69(4):504-510. DOI: 10.23736/S2724-5985.22.03156-4. View